Intellia Therapeutics (NTLA) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is NTLA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of Investor Relations & C…

Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. reg…

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean s…

NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.…

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.…

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentatio…

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov. 18 to include up to …

CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses bas…

BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.…

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on …

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.…

Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an "underweight" rating and a $8.00 price ta…

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core techno…

Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two bus…

Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis a…

NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its first product, while nex-z studies are progressing well.…

Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $12.10 and traded as low as $11.37. I…

Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Jan 22. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

